Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Current Leases (2016 - 2025)

Amicus Therapeutics filings provide 10 years of Current Leases readings, the most recent being $8.7 million for Q4 2025.

  • On a quarterly basis, Current Leases rose 3.38% to $8.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $8.7 million, a 3.38% increase, with the full-year FY2025 number at $8.7 million, up 3.38% from a year prior.
  • Current Leases hit $8.7 million in Q4 2025 for Amicus Therapeutics, up from $8.7 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $8.7 million in Q4 2025 to a low of $6.8 million in Q1 2021.
  • Median Current Leases over the past 5 years was $8.1 million (2023), compared with a mean of $8.0 million.
  • Biggest five-year swings in Current Leases: decreased 16.56% in 2021 and later grew 15.43% in 2022.
  • Amicus Therapeutics' Current Leases stood at $7.4 million in 2021, then increased by 15.43% to $8.6 million in 2022, then decreased by 2.67% to $8.3 million in 2023, then increased by 1.57% to $8.5 million in 2024, then grew by 3.38% to $8.7 million in 2025.
  • The last three reported values for Current Leases were $8.7 million (Q4 2025), $8.7 million (Q3 2025), and $8.6 million (Q2 2025) per Business Quant data.